This week public money paid for the parts of deep tech that no single company can carry. Norway funded a launch pad before a second rocket had signed for it, and the EU's pilot line in Leuven took on a Swedish start-up's etch process because its customers wanted proof first.
Private capital moved where the path was clear: a Novo-led syndicate put EUR 130 million into two Nordic drug developers in two days. NXP's newest fab also opened fully booked, in Singapore.
Lead
Norway Builds the Second Pad Before It Has a Second Rocket
The Norwegian government said on 30 September it will spend NOK 646.6 million, about EUR 60 million, on a second orbital launch pad at Andøya. NOK 323.3 million is in the 2027 budget, due on 7 October, and the rest follows in 2028, when the pad should be ready.
The state will own it, Forsvarsbygg will build it, and Andøya Space will lease it. Earlier plans tied a second pad to Andøya Space first signing another launch company.
The first pad is fully booked by Isar Aerospace, whose Spectrum reached orbit from it on 5 September after a summer of slips. Oslo is now carrying the demand risk itself, a bet that European launchers will need a sovereign pad outside French Guiana sooner than they can pay for one.
(NRK)
Biotech & Life Sciences
AnaCardio Raises EUR 62.5 Million for a Safer Way to Strengthen the Heart
Swedish AnaCardio raised a EUR 62.5 million Series B on 30 September, co-led by Novo Holdings and the Ljungström family office.
AC01 is an oral drug that activates the ghrelin receptor to make heart muscle contract harder. Existing inotropes do the same but can trigger arrhythmias, so doctors use them only briefly; in AnaCardio's Phase 1b/2a trial, AC01 raised cardiac output by 22 per cent in four weeks with no new sustained arrhythmias.
The round funds a 400-patient Phase 2b in 12 countries, starting this quarter. The goal is a Phase 3-ready drug by 2028, built on research from Lars Lund's lab at Karolinska Institutet.
(Allsci)
The Same Investors Back a Copenhagen Eye Drug a Day Earlier
Breye Therapeutics in Copenhagen closed a EUR 67.5 million Series A on 29 September, co-led by Mission BioCapital and Novo Holdings. Sound Bioventures, Innovestor Life Science, and the Ljungström family office sit in both rounds.
Breye's danegaptide is a pill meant to stop small retinal vessels leaking in early diabetic retinopathy. A Phase 1b showed reduced leakage, and a randomised Phase 2 starts in 2027.
Novo's investment arm anchored both rounds, which together brought EUR 130 million into the region in two days. Rounds this size close in the Nordics because Novo Holdings is there; it also means much of Nordic biotech rests on one investor's judgement.
Quantum & Photonics
Alice & Bob Swaps a Microwave Pump for a Microvolt
Alice & Bob and ENS Lyon reported on 1 October that a DC bias of about a microvolt can stabilise cat qubits, replacing the microwave pump normally used. The pump adds heat inside the fridge and parasitic effects that cut fidelity.
Changing only the voltage switched the coupler between exchanging photons one, two, or four at a time. Four-photon exchange is what four-component cat codes need, and those codes offer more protection against errors.
Heat and wiring inside the cryostat limit how large a superconducting machine can grow. The result is an arXiv preprint, not yet peer reviewed.
Delft Takes Entanglement Onto a Commercial Fibre Route
Eurofiber and Delft Networks, a 2024 QuTech spin-out led by Ronald Hanson, will test an entanglement link between Delft and Rotterdam over Eurofiber's dark fibre. They plan to connect on-chip quantum memories at each end and measure loss, synchronisation, and stability on an operational route.
No entanglement has been distributed over the link yet. Hanson's group has spent a decade proving long-distance entanglement in the lab; running it on a carrier's fibre tests whether quantum networks can use the infrastructure Europe already owns.
Space
EarthCARE Shows Air Traffic Where the Ash Is
ESA said on 1 October that EarthCARE, its cloud and aerosol satellite built with JAXA, profiled the plume from Indonesia's Anak Krakatau eruption on 4 and 5 September. Its lidar and radar separated sulphate, fine ash, and coarse ash, and traced the plume to about 15 km, well above the 10.7 km where most airliners cruise.
The Darwin Volcanic Ash Advisory Centre used the data during an eruption that grounded thousands of flights. A research satellite feeding an operational safety service in real time is the return Earth observation budgets promise, and the link is rarely this direct.
(ESA)
Robotics & Automation
NEURA Takes Its Robots Into Hospitals, Starting With Empty Beds
NEURA Robotics launched NEURA HealthTech at a VDMA summit in Düsseldorf on 29 and 30 September. Its first product is an autonomous platform that moves empty beds and sterile goods, rented to hospitals through partners for a monthly fee.
NEURA says 20 moves a day could save a hospital more than 1,300 staff hours a year. That is a company projection; no hospital has been named, and its MiPA service robot has no launch date for wards.
It is NEURA's first named market since its USD 1.4 billion round in June. A bed mover is a modest job for a humanoid company; it is also dull and measurable, which is how understaffed hospitals will judge whether robots pay.
Semiconductors
Imec Puts a Swedish Etch Process on Full Wafers
AlixLabs, an equipment developer from Lund, has started a six-month evaluation of its atomic layer etch pitch-splitting process in the NanoIC pilot line at Imec. The process splits one patterned line into two, which could double pattern density with fewer steps than multiple patterning.
Imec will check uniformity, roughness, pitch errors, and defects on full wafers. AlixLabs says potential customers asked for that validation; NanoIC, the largest EU Chips Act pilot line, exists for exactly this handover from a small company's lab to a fab's qualification process.
NXP's New Fab Opens Fully Booked, in Singapore
VSMC, a 60:40 venture of Taiwan's Vanguard International Semiconductor and NXP, opened its USD 7.8 billion 300 mm fab in Singapore on 28 September. It will make 40 to 130 nm power, sensing, and automotive chips on TSMC-licensed processes, reaching 44,000 wafers a month by 2029.
It went from groundbreaking to opening in under two years, and with capacity already booked the partners are weighing a second phase. NXP is also a partner in ESMC in Dresden, but its fastest-growing source of mature-node chips is in Asia.
One to Watch
Europe's Own Space Station Goes to Ministers in Rome
ESA picked Airbus Defence and Space and OHB on 29 September to lead studies of a European-led station in low Earth orbit, built on Columbus and the Orion service module. Development spending would be capped at EUR 1 billion per three-year period, for two periods at most.
Member states will weigh the options at an intermediate ministerial meeting in Rome on 15 December. Watch whether Rome funds a station or more studies, and whether commercial cargo such as The Exploration Company's Nyx, which has an ESA contract worth up to EUR 760 million to fly to the ISS in 2028, is written into the plan.